Thursday, April 14, 2011
According to Booth, one problem facing early investors is the
different standards of data quality between bleeding-edge academic research and
the sort of robust assays needed for drug development in industry.
Camille Samuels, a managing director at Versant
Ventures, cautioned that putting researchers on the
spot to prove their data could set a bad tone for subsequent relations with a
Osherovich, L. SciBX 4(15); doi:10.1038/scibx.2011.416
Published online April 14, 2011
Institutes of Health, Bethesda, Md.
Menlo Park, Calif.